Equity Overview
Price & Market Data
Price: $1.25
Daily Change: +$0.05 / 4.00%
Range: $1.21 - $1.29
Market Cap: $23,193,618
Volume: 41,469
Performance Metrics
1 Week: 8.54%
1 Month: 10.45%
3 Months: -40.61%
6 Months: -22.75%
1 Year: 90.80%
YTD: -30.44%
Company Details
Employees: 16
Sector: Health technology
Industry: Biotechnology
Country: Israel
Details
Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases in the United States. Its lead product candidate is CM-101, a humanized monoclonal antibody attenuates the basic function of CCL24 that is in phase 2 clinical trial for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.